If you are one of the millions of Americans trying to quit smoking, keep up the good work. It isn't easy, but the payoffs are huge. If you are using the quit-smoking drug Chantix (varenicline), there's a new bump in the road: for people with heart disease, the FDA says the drug slightly increases the chances of having a heart attack or other cardiovascular problem. A Canadian study concludes that use of the drug increases the risk of heart attack, stroke, and heart failure in all users (CMAJ, July 4, 2011).
The FDA approved Chantix in 2006 based on clinical trial results that it doubled the quit rate (10% for placebo, 23% for Chantix). The drug works by latching onto nicotine receptors in the brain and activating them, much as nicotine does. This reduces a smoker's craving for nicotine and eases withdrawal symptoms.
To continue reading this article, you must log in.
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.
- Research health conditions
- Check your symptoms
- Prepare for a doctor's visit or test
- Find the best treatments and procedures for you
- Explore options for better nutrition and exercise
I'd like to receive access to Harvard Health Online for only $4.99 a month.Sign Me Up
Already a member? Login ».
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.